Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $683.71 | 14 | 96.5% |
| Consulting Fee | $25.00 | 1 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GM Pharmaceuticals, Inc. | $495.38 | 2 | $0 (2020) |
| SANOFI PASTEUR INC. | $39.00 | 2 | $0 (2019) |
| Genentech USA, Inc. | $34.87 | 2 | $0 (2021) |
| Otsuka America Pharmaceutical, Inc. | $32.18 | 2 | $0 (2024) |
| Amarin Pharma Inc. | $28.70 | 2 | $0 (2020) |
| Novo Nordisk Inc | $18.52 | 1 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $17.09 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $15.74 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $13.90 | 1 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $13.33 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $79.77 | 5 | Otsuka America Pharmaceutical, Inc. ($32.18) |
| 2021 | $34.87 | 2 | Genentech USA, Inc. ($34.87) |
| 2020 | $267.28 | 4 | GM Pharmaceuticals, Inc. ($224.68) |
| 2019 | $309.70 | 3 | GM Pharmaceuticals, Inc. ($270.70) |
| 2017 | $17.09 | 1 | Janssen Pharmaceuticals, Inc ($17.09) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: PSYCHIATRY | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/26/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: PSYCHIATRY | ||||||
| 08/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Cardio-renal | ||||||
| 01/15/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Virology & Specialty Care | ||||||
| 01/05/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Virology & Specialty Care | ||||||
| 07/08/2020 | GM Pharmaceuticals, Inc. | Vanacof (Drug), Cozima | Food and Beverage | In-kind items and services | $224.68 | General |
| Category: Cough and Cold | ||||||
| 03/06/2020 | Merck Sharp & Dohme Corporation | ROTATEQ (Biological), PNEUMOVAX 23, VAQTA | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: VACCINE | ||||||
| 02/27/2020 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Cardiovascular | ||||||
| 02/03/2020 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Cardiovascular | ||||||
| 05/28/2019 | GM Pharmaceuticals, Inc. | Vanacof (Drug) | Food and Beverage | In-kind items and services | $270.70 | General |
| Category: Cough and Cold | ||||||
| 04/24/2019 | SANOFI PASTEUR INC. | PENTACEL (Drug), MENACTRA, QUADRACEL | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: VACCINES | ||||||
| 01/25/2019 | SANOFI PASTEUR INC. | NO PRODUCT DISCUSSED (Drug) | Consulting Fee | In-kind items and services | $25.00 | General |
| 01/23/2017 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 6 | 444 | 448 | $22,893 | $13,197 |
| 2020 | 8 | 453 | 529 | $60,553 | $33,073 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 213 | 213 | $11,118 | $6,866 | 61.8% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 136 | 137 | $4,098 | $2,424 | 59.2% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2021 | 35 | 35 | $3,736 | $1,796 | 48.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 12 | 12 | $2,400 | $1,366 | 56.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 11 | $1,540 | $744.48 | 48.3% |
| 91301 | Sarscov2 vac 100mcg/0.5ml im | Office | 2021 | 37 | 40 | $0.40 | $0.40 | 100.0% |
| 99343 | New patient home visit, typically 45 minutes | Office | 2020 | 64 | 64 | $12,560 | $7,937 | 63.2% |
| 99349 | Established patient home visit, typically 40 minutes | Office | 2020 | 30 | 53 | $10,529 | $6,894 | 65.5% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2020 | 115 | 128 | $10,497 | $6,568 | 62.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 63 | 80 | $11,200 | $4,638 | 41.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 54 | 54 | $10,800 | $4,593 | 42.5% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2020 | 91 | 91 | $2,407 | $1,516 | 63.0% |
| 87804 | Detection test for influenza virus | Office | 2020 | 23 | 46 | $2,300 | $728.20 | 31.7% |
| 87880 | Strep test (streptococcus, group a) | Office | 2020 | 13 | 13 | $260.00 | $198.36 | 76.3% |
About Dr. Ana Flanagan, MD
Dr. Ana Flanagan, MD is a Family Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2011. The National Provider Identifier (NPI) number assigned to this provider is 1780962100.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ana Flanagan, MD has received a total of $708.71 in payments from pharmaceutical and medical device companies, with $79.77 received in 2024. These payments were reported across 15 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($683.71).
As a Medicare-enrolled provider, Flanagan has provided services to 897 Medicare beneficiaries, totaling 977 services with total Medicare billing of $46,270. Data is available for 2 years (2020–2021), covering 14 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Houston, TX
- Active Since 08/02/2011
- Last Updated 08/11/2021
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1780962100
Products in Payments
- Vanacof (Drug) $495.38
- Xofluza (Drug) $34.87
- REXULTI (Drug) $32.18
- Vascepa (Drug) $28.70
- NO PRODUCT DISCUSSED (Drug) $25.00
- Ozempic (Drug) $18.52
- INVOKANA (Drug) $17.09
- FARXIGA (Drug) $15.74
- PENTACEL (Drug) $14.00
- ROTATEQ (Biological) $13.90
- Kerendia (Drug) $13.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Houston
Shannon Schrader, Md, MD
Family Medicine — Payments: $383,042
Dr. Eric Nolen, Md, Mba, MD, MBA
Family Medicine — Payments: $158,026
Candice Winful, M.d, M.D
Family Medicine — Payments: $123,290
Dr. Joe Pouzar, M.d, M.D
Family Medicine — Payments: $104,957
Victor Escobar, M.d, M.D
Family Medicine — Payments: $79,840
Dr. Oscar De Valle, M.d, M.D
Family Medicine — Payments: $78,226